BB Biotech AG operates in the Investors sector.
In addition to historical fundamental analyses, the complete report available to purchase compares BB Biotech AG with three other
financial institutions in Europe:
Deutsche Balaton AG
sales of 186.45 million Euro [US$211.39 million]
of which 38%
(2.79 billion Swedish Kronor [US$306.82 million]
of which 100%
was Portfolio Management), and
based in France
(235.02 million Euro [US$266.46 million]
of which 81%
was Financial Investments).
Sales increased substantially in 2017:
BB Biotech AG reported sales of 270.33 million Swiss Francs (US$268.72 million)
December of 2017.
increase of 2,122.9%
versus 2016, when the company's sales were 12.16 million Swiss Francs.
Despite this increase, sales are still
below the level achieved in 2015, when BB Biotech AG
reported sales of 292.00 million Swiss Francs.